Bevacizumab treatment in hereditary hemorrhagic teleangiectasia
✍ Scribed by Sebastian Föllner, Michael Ibe, Jens Schreiber
- Book ID
- 120759291
- Publisher
- Springer
- Year
- 2012
- Tongue
- English
- Weight
- 78 KB
- Volume
- 68
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objectives/Hypothesis: Determine the effectiveness of treating epistaxis in hereditary hemorrhagic telangiectasia (HHT) with potassium titanyl phosphate (KTP) laser cautery combined with submucosal injection of 100 mg of bevacizumab. ## Study Design: Retrospective pilot study. ##
## Abstract ## Objectives/Hypothesis: Assess for complications of intranasal Bevacizumab application in patients with hereditary hemorrhagic telangiectasia (HHT)‐associated epistaxis. ## Study Design: Retrospective chart review. ## Methods: In 58 patients presenting with recurrent HHT epistaxi
## Abstract ## Objectives/ Hypothesis: Intranasal Bevacizumab is an effective therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). ## Study Design: Retrospective chart review. ## Methods: In 32 successive patients presenting with recurrent HHT epistaxis 25–100 mg